Keine News vorhanden

“Izvestia”: the cost of treatment for hepatitis C will decrease in Russia due to generics

The authorities are considering the possibility of forcibly licensing domestic analogues of drugs for hepatitis C, this will significantly reduce the cost of treatment, the newspaper “Izvestia”.

“Izvestia”: the cost of treatment for hepatitis C will decrease in Russia due to generics
10.03.2025
Lesezeit: 2 min
24 mal angesehen
“Izvestia”: self-ban on loans began to be used in fraudulent schemes

12.03.2025

“Izvestia”: self-ban on loans began to be used in fraudulent schemes

“Izvestia”: farms fear drought and crop loss in 2025

09.03.2025

“Izvestia”: farms fear drought and crop loss in 2025

Drive. Izvestia and Al Mayadeen signed a cooperation agreement

20.03.2025

Drive. Izvestia and Al Mayadeen signed a cooperation agreement

“Izvestia”: the number of IP in Russia increased by almost a quarter

08.03.2025

“Izvestia”: the number of IP in Russia increased by almost a quarter

MegaFon and Yota canceled roaming in the Crimea and Sevastopol

28.02.2025

MegaFon and Yota canceled roaming in the Crimea and Sevastopol

“Izvestia”: in Russia want to introduce criminal punishment for dog owners

17.03.2025

“Izvestia”: in Russia want to introduce criminal punishment for dog owners

Drive. Lipetsk surgeons performed a complex operation using C-arc with angioregime

26.03.2025

Drive. Lipetsk surgeons performed a complex operation using C-arc with angioregime

“Izvestia”: in Russia will develop a state rating of universities and colleges

06.03.2025

“Izvestia”: in Russia will develop a state rating of universities and colleges

Izvestia: Rosgvardia will be engaged in the training of employees of CPF

10.03.2025

Izvestia: Rosgvardia will be engaged in the training of employees of CPF

Izvestia: the total cost of consumer loans increased to 37%

10.03.2025

Izvestia: the total cost of consumer loans increased to 37%

“Izvestia”: self-ban on loans began to be used in fraudulent schemes

12.03.2025

“Izvestia”: self-ban on loans began to be used in fraudulent schemes

“Izvestia”: farms fear drought and crop loss in 2025

09.03.2025

“Izvestia”: farms fear drought and crop loss in 2025

Drive. Izvestia and Al Mayadeen signed a cooperation agreement

20.03.2025

Drive. Izvestia and Al Mayadeen signed a cooperation agreement

“Izvestia”: the number of IP in Russia increased by almost a quarter

08.03.2025

“Izvestia”: the number of IP in Russia increased by almost a quarter

MegaFon and Yota canceled roaming in the Crimea and Sevastopol

28.02.2025

MegaFon and Yota canceled roaming in the Crimea and Sevastopol

“Izvestia”: in Russia want to introduce criminal punishment for dog owners

17.03.2025

“Izvestia”: in Russia want to introduce criminal punishment for dog owners

Drive. Lipetsk surgeons performed a complex operation using C-arc with angioregime

26.03.2025

Drive. Lipetsk surgeons performed a complex operation using C-arc with angioregime

“Izvestia”: in Russia will develop a state rating of universities and colleges

06.03.2025

“Izvestia”: in Russia will develop a state rating of universities and colleges

Izvestia: Rosgvardia will be engaged in the training of employees of CPF

10.03.2025

Izvestia: Rosgvardia will be engaged in the training of employees of CPF

Izvestia: the total cost of consumer loans increased to 37%

10.03.2025

Izvestia: the total cost of consumer loans increased to 37%

📝 Summary

The authorities are considering the possibility of forcibly licensing domestic analogues of drugs for hepatitis C, this will significantly reduce the cost of treatment, the newspaper “Izvestia”.

The Federal Antimonopoly Service (FAS) has already agreed on prices for Russian generics "Velpatasof" and "Pigleria". Their price will be 40% lower than imported original medicines. According to the chief freelance infectious disease specialist of the Ministry of Health, whose words are cited by Izvestia, this will allow a quarter increase in the number of patients receiving treatment in 2025. Now in Russia, treatment of hepatitis C is carried out only with imported drugs, among them Irish "Epcluse", "Maviret", "Sovaldi". Until 2023, the American Zepatir was actively used, which provided 20% of public procurement, but the drug was withdrawn from the market due to sanctions. However, at the end of 2022, Russian pharmaceutical companies Pharmasintez, Geropharm and Pharmstandard received permission to develop generics for Maviret and Epclusa drugs, despite existing patents. The service has agreed prices for the domestic drug "Velpatasof" under the international non-proprietary name "Velpatasvir + Sofosbuvir". Its cost will be 40% lower than the original “Epcluse”, – said the FAS. The price of packaging an analogue of 28 tablets will be 68.7 thousand rubles, while the imported analogue costs 114.5 thousand rubles. In addition, the domestic analogue of the Pigleria will be 40% cheaper than the original Maviret, whose cost per package exceeds 171 thousand rubles. Earlier, the media wrote that from 2025, Russians will be able to receive new drugs for cancer and hepatitis C.

Reagiere auf diesen Beitrag
Telegram Подписаться на NX Россия

Новые видео

← Back to News

🕒 Zuletzt Angesehen